Swiss Life Asset Management’s Oruka Therapeutics ORKA Stock Holding History

Swiss Life Asset Management’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Buy	+2,122	New	+$141K	﹤0.01%	1522

Other funds holding ORKA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Swiss Life Asset Management's ORKA Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 2,122 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #1522 among its holdings.

121 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

Swiss Life Asset Management held 2,122 shares of Oruka Therapeutics worth $202K as of Q2 2026.
Oruka Therapeutics was a new Swiss Life Asset Management position in Q2 2026.
Oruka Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1522 holding.
121 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.